p53 Expression in Langerhans cell histiocytosis

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 1, 1998, Pages 12-17

  Weintraub, Michael ^a   Bhatia, Kishor G ^a   Chandra, Roma S ^b   Magrath, Ian T ^a   Ladisch, Stephan ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

CD1a; Cell proliferation; Langerhans cell histiocytosis; LCH cells; p53

Indexed keywords

PROTEIN P53;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DEATH; CELL PROLIFERATION; DNA REPAIR; GENE MUTATION; HISTIOCYTOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LANGERHANS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GENES, P53; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MUTATION; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031934440     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199801000-00002     Document Type: Article

References (41)

1. Favara B. Langerhans cell histiocytosis: pathobiology and pathogenesis. Semin Oncol 1991;18:3-7.
2. Nezelof C, Basset F, Rousseaeu MF. Histiocytosis X: histogenetic arguments for a Langerhans cell origin. Biomedicine 1973;18:365-71.
3. Chu T, Jaffe R. The normal Langerhans cell and the LCH cell. Br J Cancer 1994;70:S4-10 (suppl).
4. Broadbent V, Egeler M, Nesbit ME. Langerhans cell histiocytosis -Clinical and epidemiological aspects. Br J Cancer 1994;70:S11-6 (suppl).
5. Ladisch S. Histiocytosis. In Willoughby MLN and Siegal SE (eds). Butterworths' International Medical Reviews. Pediatrics, Vol. 1, Hematology/Oncology. London: Butterworth Scientific, 1982:95-109.
6. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer 1994;70:S37-40 (suppl).
7. Willman CL, Busque L, Griffith B, et al. Langerhans-cell histiocytosis - A clonal proliferative disease. N Engl J Med 1994;331:154-60.
8. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994;343:767-8.
9. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
10. McClain K, Hong J, Gresik V. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol 1994;47:16-20.
11. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
12. Writing group of the histiocyte society (Chu T, D'Angio GJ, Favara B, Ladisch S, Nesbit M, Pritchard J). Histiocytosis syndromes in children. Lancet 1987;1:208-9.
13. Hsu M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique. J Histochem Cytochem 1981;29:577-80.
14. Bhatia K, Goldschmidts W, Gutierrez M, et al. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J 1993;7:951-6.
15. Masuda H. Miller C. Koeffler HP, et al. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 1987;84:7716-9.
16. Orita M, Iwahara H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766-70.
17. Bhatia KG, Gutierrez MI, Huppi K, et al. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 1992;52:4273-6.
18. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3:2143-50.
19. Hall PA, Lane DP. p53 in tumor pathology: Can we trust immunohistochemistry? - Revisited. J Pathol 1994;172:1-4.
20. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
21. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
22. Levine AJ. The p53 protein and its interactions with the oncogene products of small DNA tumor viruses. Virology 1990;177:419-26.
23. Sarnow P, Ho YS, Williams J, et al. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 1982';28:387-94.
24. Feitelson MA, Zhu M, Duan LX, et al. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-17.
25. Szekely L, Selivanova G, Magnusson KP, et al. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 1993;90:5455-9.
26. Zhang Q, Gutsch D, Kenney S. Functional and physical interactions between p53 and BZLF1 : implications for Epstein-Barr virus latency. Mol Cell Biol 1994;14:1929-38.
27. Donehower LA, Bradley A. The tumor suppressor p53. Biochem Biophysic Acta 1993;1155:181-205.
28. Wu X, Boyle JH, Olson DC, et al. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
29. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
30. Chilosi M, Doglioni C, Menestrina F, et al. Abnormal expression of the p53-binding protein mdm2 in Hodgkin's disease. Blood 1994;84:4295-300.
31. Bames DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 in normal cells of a cancer family patient. Lancet 1992;340:259-63.
32. Vojtesek B, Bartek J, Midgley CA. An immunohistochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992;151:237-44.
33. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
34. Gusterson BA, Anbazhagan R, Warren W, et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991;6:1785-9.
35. Sasano H, Miyazaki S, Gooukon Y, et al. Expression of p53 in human esophageal carcinoma: An immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 1992;23:1238-43.
36. Porter PL, Gown AM, Kramp SG, et al. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992;140:145-53.
37. Hall PA, McKee PH, Menage HP, et al. High levels of p53 in UV-irradiated normal human skin. Oncogene 1993;8:203-7.
38. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
39. Merritt AJ, Potten CS, Kemp CJ, et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994;54:614-7.
40. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptsis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-7.
41. White E. Life, death and the pursuit of apoptosis. Genes Dev 1996;10:1-15.